Janssen Pharmaceuticals Inc.

05/23/2022 | Press release | Distributed by Public on 05/23/2022 08:37

New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD)[...]